Y. Abubakr

Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.

C. Chow, R. Mohammad, A. Al-Katib, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

The role of immunotherapy in urologic malignancies.

B. Redman, Y. Abubakr, 1996, Cancer treatment and research.

Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.

R. Mohammad, M. Dugan, A. Al-Katib, 1996, Leukemia.

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).

W. Scheithauer, A. Zubel, J. Maurel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spontaneous remission of renal cell carcinoma: a case report and immunological correlates.

B. Redman, T. Chou, Y. Abubakr, 1994, The Journal of urology.

Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL.

R. Mohammad, A. Al-Katib, T. Xie, 1995, Cancer gene therapy.

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

J. Hainsworth, L. Hart, L. Fehrenbacher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

W. Scheithauer, H. Lenz, A. Zubel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of recombinant interleukin-1β in patients with metastatic renal cell carcinoma

B. Redman, T. Chou, L. Flaherty, 1994 .

The Next Step in Your Career: Getting the Right Opportunity and the Right Contract.

C. Verschraegen, Y. Abubakr, Mark Lee, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

W. Scheithauer, A. Zubel, J. Maurel, 2005 .